Protalix Biotherapeutics Company Profile (NYSEMKT:PLX)

About Protalix Biotherapeutics (PLX)

Protalix Biotherapeutics logoProtalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSEMKT
  • Symbol: PLX
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $1.14
  • 50 Day Moving Average: $1.09
  • 200 Day Moving Average: $0.64
  • 52-Week Range: $0.26 - $1.51
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.33
  • P/E Growth: -0.16
  • Market Cap: $139.03M
  • Outstanding Shares: 99,821,000
  • Beta: 0.95

Analyst Ratings

Consensus Ratings for Protalix Biotherapeutics (NYSEMKT:PLX) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $1.77

Analysts' Ratings History for Protalix Biotherapeutics (NYSEMKT:PLX)
Show:
DateFirmActionRatingPrice TargetDetails
12/15/2016MackieReiterated RatingBuy$1.00View Rating Details
9/6/2016Jefferies Group LLCLower Price TargetBuy$1.75 -> $0.80View Rating Details
7/11/2016Rodman & RenshawReiterated RatingBuyView Rating Details
(Data available from 3/26/2015 forward)

Earnings

Earnings History for Protalix Biotherapeutics (NYSEMKT:PLX)
Earnings by Quarter for Protalix Biotherapeutics (NYSEMKT:PLX)
Earnings History by Quarter for Protalix Biotherapeutics (NYSEMKT:PLX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2017        
8/8/2016Q2 16($0.08)($0.11)$1.34 million$1.77 millionViewN/AView Earnings Details
3/8/2016Q415($0.29)$3.50 million$4.40 millionViewN/AView Earnings Details
11/10/2015Q3 15($0.08)($0.04)ViewN/AView Earnings Details
8/11/2015Q215($0.08)($0.05)ViewN/AView Earnings Details
5/7/2015Q1 15($0.08)($0.06)ViewN/AView Earnings Details
8/15/2014($0.07)($0.07)ViewN/AView Earnings Details
5/22/2014($0.07)($0.08)ViewN/AView Earnings Details
3/13/2014Q413($0.02)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Protalix Biotherapeutics (NYSEMKT:PLX)
Current Year EPS Consensus Estimate: $-0.28 EPS
Next Year EPS Consensus Estimate: $-0.21 EPS

Dividends

Dividend History for Protalix Biotherapeutics (NYSEMKT:PLX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Protalix Biotherapeutics (NYSEMKT:PLX)
Insider Trades by Quarter for Protalix Biotherapeutics (NYSEMKT:PLX)
Institutional Ownership by Quarter for Protalix Biotherapeutics (NYSEMKT:PLX)
Insider Trades by Quarter for Protalix Biotherapeutics (NYSEMKT:PLX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2016Camber Capital Management LlcMajor ShareholderSell2,500,000$0.32$800,000.00View SEC Filing  
12/14/2015Yossi MaimonCFOBuy10,000$0.78$7,800.00View SEC Filing  
10/19/2015Camber Capital Management LlcMajor ShareholderBuy4,000,423$1.00$4,000,423.00View SEC Filing  
8/15/2013Alfred AkirovDirectorSell112,330$5.05$567,266.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Protalix Biotherapeutics (NYSEMKT:PLX)
Latest Headlines for Protalix Biotherapeutics (NYSEMKT:PLX)
Source:
DateHeadline
americanbankingnews.com logoProtalix Biotherapeutics Inc (PLX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 22 at 6:01 PM
seekingalpha.com logoProtalix BioTherapeutics: Exploring Ulcerative Colitis - Seeking Alpha
seekingalpha.com - March 16 at 8:31 AM
biz.yahoo.com logoQ4 2016 Protalix Biotherapeutics Inc Earnings Release - Time Not Supplied
biz.yahoo.com - March 16 at 8:31 AM
finance.yahoo.com logoProtalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporate Update
finance.yahoo.com - March 16 at 8:31 AM
biz.yahoo.com logoPROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - March 16 at 8:31 AM
americanbankingnews.com logoProtalix Biotherapeutics Inc (PLX) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 15 at 8:19 AM
globenewswire.com logoProtalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16 ... - GlobeNewswire (press release)
globenewswire.com - March 9 at 7:06 PM
bizjournals.com logoTechnical Reports on Biotech Stocks -- Juno Therapeutics, Protalix BioTherapeutics, ImmunoGen, and ContraVir Pharma
www.bizjournals.com - February 23 at 8:58 AM
seekingalpha.com logoProtalix BioTherapeutics: New Institutional Ownership Swells Ahead Of Major Catalysts
seekingalpha.com - February 21 at 5:35 PM
biz.yahoo.com logoPROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure
biz.yahoo.com - February 16 at 6:52 PM
us.rd.yahoo.com logoProtalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders
us.rd.yahoo.com - February 14 at 11:33 PM
globenewswire.com logoProtalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders - GlobeNewswire (press release)
globenewswire.com - February 14 at 11:33 PM
globenewswire.com logoProtalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017 - GlobeNewswire (press release)
www.globenewswire.com - February 14 at 4:21 AM
seekingalpha.com logoProtalix continues up move, shares ahead 27% - Seeking Alpha
seekingalpha.com - February 14 at 4:21 AM
finanznachrichten.de logoGainers & Losers Of The Day: ZSAN, PLSE, XOMA, SAGE, CBIO...
www.finanznachrichten.de - February 13 at 11:19 PM
us.rd.yahoo.com logoProtalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017
us.rd.yahoo.com - February 13 at 11:19 PM
us.rd.yahoo.com logo8:42 am Protalix BioTherapeutics outperforming ahead of the open after previewing its presentations at this week's Annual WORLDSymposium (2/13-2/17)
us.rd.yahoo.com - February 13 at 11:19 PM
globenewswire.com logoProtalix BioTherapeutics to Participate in the 13th Annual ... - GlobeNewswire (press release)
globenewswire.com - February 13 at 9:14 AM
zacks.com logoProtalix BioTherapeutics (PLX) Jumps: Stock Rises by 11.7%
www.zacks.com - January 30 at 8:28 AM
streetinsider.com logoKnight Therapeutics Acquires 6.2M Shares of Protalix ... - StreetInsider.com
www.streetinsider.com - January 30 at 12:44 AM

Social

Frequently Asked Questions for Protalix Biotherapeutics (NYSEMKT:PLX)

What is Protalix Biotherapeutics' stock symbol?

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "PLX."

How were Protalix Biotherapeutics' earnings last quarter?

Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced its quarterly earnings results on Monday, August, 8th. The company reported ($0.11) EPS for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.03. The company had revenue of $1.77 million for the quarter, compared to the consensus estimate of $1.34 million. During the same quarter in the prior year, the firm earned ($0.05) EPS.

When will Protalix Biotherapeutics make its next earnings announcement?

Protalix Biotherapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March, 16th 2017.

Where is Protalix Biotherapeutics' stock going? Where will Protalix Biotherapeutics' stock price be in 2017?

3 brokerages have issued 12-month target prices for Protalix Biotherapeutics' shares. Their forecasts range from $0.80 to $3.50. On average, they expect Protalix Biotherapeutics' stock price to reach $1.77 in the next twelve months.

Who owns Protalix Biotherapeutics stock?

Protalix Biotherapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.48%). Company insiders that own Protalix Biotherapeutics stock include Camber Capital Management Llc and Yossi Maimon.

Who bought Protalix Biotherapeutics stock? Who is buying Protalix Biotherapeutics stock?

Protalix Biotherapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Protalix Biotherapeutics stock in the last two years include Camber Capital Management Llc and Yossi Maimon.

How do I buy Protalix Biotherapeutics stock?

Shares of Protalix Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Protalix Biotherapeutics stock cost?

One share of Protalix Biotherapeutics stock can currently be purchased for approximately $1.12.


This page was last updated on 3/26/2017 by MarketBeat.com Staff